0001415889-25-022683.txt : 20250821 0001415889-25-022683.hdr.sgml : 20250821 20250821210927 ACCESSION NUMBER: 0001415889-25-022683 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250821 DATE AS OF CHANGE: 20250821 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 251242060 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: McAuliffe Sean CENTRAL INDEX KEY: 0001979693 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: C/O TAYSHA GENE THERAPIES, INC. STREET 2: 3000 PEGASUS PARK DRIVE, SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 144 1 primary_doc.xml 144 0001979693 XXXXXXXX LIVE 0001806310 TAYSHA GENE THERAPIES, INC. 001-39536 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 214-612-0000 Sean McAuliffe Affiliate - Chief Business Officer Common Stock Maxim Group LLC

300 Park Avenue, 16th Floor New York NY 10022

27590 79183.30 272794885 08/21/2025 Nasdaq Common Stock 08/21/2025 RSU Award Issuer N 27590 08/21/2025 Vested grant settled instock; consideration was Reporting Person's continued service as an employee ofthe Issuer. Y The Reporting Person is selling the securities set forth herein pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. 08/21/2025 /s/ Sean McAuliffe